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As our population ages, diseases of low bone mass, including osteopenia and osteoporosis, are 
increasing in prevalence.  In the elderly, low bone mass is a significant risk for fragility fractures, 
associated with increased morbidity and mortality.  Age-related bone loss is thought to occur due to 
an imbalance between bone-forming osteoblasts and bone-resorbing osteoclasts as a result of 
decreased osteoblast differentiation from mesenchymal stem cells (MSCs).  Current treatments for 
low bone mass are limited, where most interventions slow the rate of bone loss rather than rebuilding 
bone mass.  Increasing amino acid (AA) intake through a high protein diet is associated with increased 
bone formation and decreased fracture risk, thought to occur through increased IGF-1, a potent bone 
anabolic factor.  The mTORC1 complex is a major anabolic signalling pathway, responsive to 
arginine, leucine and IGF-1.  Previous studies have established that mTORC1 dysfunction in 
osteoblasts causes low bone mass and skeletal fragility in genetic mouse models.  The aim of this 
study was to investigate if AAs (arginine and leucine) and IGF-1 promote bone mass by stimulating 
osteoblast differentiation in human MSCs via the mTORC1 pathway.  AAs and IGF-1 act 
synergistically to stimulate mTORC1 function in human MSCs. Moreover, under optimised 
conditions, high levels of these AAs stimulate mTORC1-dependent expression of osteogenic gene 
markers, ALPL (High AA vs. High AA + Rapamycin p=.0048) and BGLAP.  Characterising the 
mTORC1-dependent effects of AAs and IGF-1 on osteogenesis, and therefore bone formation, could 
direct dietary guidelines and identify novel drug targets for treatment of low bone mass. 




Diseases characterised by low bone mass, such as osteopenia and osteoporosis, are increasing in 
prevalence globally, consistent with a growing aged population and a shift towards a more sedentary 
lifestyle.1  Low bone mass is associated with significantly higher risk of fractures2 and considerable 
loss of quality of life due to disability and loss of independence3, as well as mortality when compared 
to age-matched populations.4  Osteoporosis, osteopenia and associated fractures also impact the 
Australian economy where an approximately threefold increase in spending was observed between 
2007 and 2017, which is only expected to increase in future years.5 
Age-related bone loss occurs due to an imbalance between the activity of bone-resorbing osteoclasts 
and bone-forming osteoblasts.6 Osteoblasts are derived from multipotent mesenchymal stem cells 
(MSCs), a population that also give rise to several other cell types including adipocytes.  The 
differentiation toward osteoblasts and adipocytes is a mutually exclusive process, spatiotemporally 
controlled by lineage-specific transcription factors.7  Adipocyte generation is primarily regulated by 
transcription factors proliferator-activated receptor gamma (PPARγ) and CCAAT-enhancer-binding 
proteins (C/EBPs) while osteoblast differentiation is controlled through Runt-related transcription 
factor 2 (RUNX2) and OSTERIX (SP7) expression.8  With age, there is a shift in MSC differentiation 
favouring adipocyte formation resulting in a corresponding decrease in osteoblast differentiation and 
osteoblast numbers8, thought to be a significant driver of age-related bone loss.9    Stimulating an 
increase in osteoblast populations and/or function could mitigate age-related bone loss. 
Treatments for bone loss are currently limited, with supplementation of calcium and vitamin D 
commonly recommended as they reduce bone loss and incidences of non-vertebral fractures in older 
individuals.10  Drugs used for the treatment of osteoporosis are also limited with bisphosphonates 
being the primary therapy.  Both interventions act to slow the rate of bone loss, however, patients will 
continue to deteriorate under these regimes.11  Anabolic therapies associated with these conditions 
have suffered drawbacks, particularly due to the sensitivity of osteoblasts to oxidative stress.8  
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Parathyroid hormone and related protein analogues are currently the only anabolic osteoporosis 
therapy, however, is recommended only to high-risk patients due to the possible risk of osteosarcoma, 
observed in some animal models.12  The lack of safe and effective anabolic therapies for long-term 
treatment represents a clinical need for therapies targeted to increasing bone mass to lessen the 
incidence and impacts of low bone mass-associated skeletal fragility fractures.11 
High dietary protein intake has been shown to promote bone anabolism and decrease the risk of 
fracture.13  Moreover, protein supplementation has been found to be protective against age-related 
bone loss while protein under-nutrition is associated with decreased bone mass.14  A longitudinal, 
population-based study in aged individuals has also found that lower protein intake is significantly 
correlated with bone loss.15  Moreover, individuals with higher dietary protein intake, over the course 
of the study, maintained their bone mineral density, even after controlling for major confounding 
factors such as weight, smoking status and alcohol intake.15  In hip fracture patients, increased protein 
intake resulted in a reduction in post-surgical bone loss and time spent in hospital16 as well as 
promoting better overall recovery.14  Mechanistically, a positive correlation has been established 
between dietary protein intake and insulin-like growth factor 1 (IGF-1) levels, indicating that the 
relationship between protein intake and bone mass may be controlled through IGF-1.17 
IGF-1 is a potent bone anabolic growth factor that directs MSCs towards an osteogenic cell fate.18  
IGF-1 levels positively correlate with bone mass and bone strength14 therefore, circulating IGF-1 
levels can be used as an informative clinical biomarker, particularly in the monitoring of osteoporotic 
patients.  IGF-1 is synthesised and secreted primarily by the liver19 but the skeleton20 has also been 
identified as a significant source.  Matrix-associated IGF-1 has been shown to stimulate osteoblast 
differentiation from MSCs as knockout of the IGF-1 receptor in pre-osteoblasts resulted in lower 
bone mass compared to wild-type mice.20  Hepatic IGF-1 production has been shown to be stimulated 
in response to amino acids (AAs).19 Moreover, AAs have been shown to improve bone mineral 
density21, with arginine in particular shown to increase IGF-1 production by osteoblast-like cells22 
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and cultured human osteoblasts from healthy23 and osteopenic24 populations, inferring that increases 
in bone mass, due to amino acids, may occur through increased IGF-1 production.  
The bone anabolic activity of IGF-1 is mediated by the mechanistic target of rapamycin complex 1 
(mTORC1).  mTORC1 is the primary nutrient sensor that also responds to other signals to control 
cell growth and proliferation.25  IGF-1 activates mTORC1 via the tuberous sclerosis complex (TSC) 
(Fig. 1).  Recently, a second arm of the pathway has been found to respond to AA stimuli.  In 
particular, mTORC1 is activated by arginine and leucine26, 27, regulated by the CASTOR and Sestrin 













Figure 1: Schematic of IGF-1 and AA-dependent facets of the mTORC1 signalling pathway.  mTORC1 
is activated in response to arginine and leucine through the Rag-GTPases and IGF-1 through Rheb, and 
inhibited by rapamycin. Activated mTORC1 drives a signal transduction cascade (via p70 S6K) leading to 




There is a growing body of evidence to suggest that mTORC1 signalling plays a significant role in 
bone formation.  Mice with conditional deletion of either mTOR or Rptor, components of the 
mTORC1 complex, in pre-osteoblasts results in impaired osteogenesis, lower bone mass and skeletal 
fragility compared to controls.29, 30  Mechanistically, loss of mTORC1 function in osteoblasts leads 
to a reduction in protein synthesis29 and downregulation of Runx2 through phosphorylation of 
Estrogen Receptor α.30  Taken together, these results suggest that IGF-1 and AA dependent activation 
of the mTORC1 pathway may play a critical role in the bone anabolic action of dietary proteins. 
A high protein diet has been shown to increase bone mass however, the mechanism by which this 
occurs is currently not fully known.1  Different branches of the mTORC1 signalling pathway respond 
to IGF-1 and the AAs arginine and leucine31, and inhibition of the mTORC1 complex inhibits IGF-
1-mediated osteoblast differentiation.29  Together, these findings suggest that the mTORC1 complex 
in MSCs plays a role in directing osteoblast differentiation in response to IGF-1, arginine and leucine.  
Understanding the mechanism by which this occurs will contribute to creating a stable knowledge 
foundation to facilitate the development of safe and effective bone anabolic therapies. 
This has led to the following hypothesis: An increase in the dietary AAs arginine and leucine 
stimulates bone mass by directing MSC osteogenic differentiation via IGF-1 and the mTORC1 
pathway.  This question will be investigated in the following aims: 
Aim 1: To demonstrate that AAs, arginine and leucine, and IGF-1 stimulate mTORC1 activity in 
human MSCs. 
Aim 2: To determine if arginine and leucine work synergistically with IGF-1 to promote osteogenesis 
via an mTORC1-dependent pathway. 
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Materials and Methods 
Reagents 
All reagents were purchased from Sigma Aldrich unless otherwise specified.   
Subjects and cell culture 
Human MSC cultures, previously isolated from bone chips recovered from the posterior iliac crest of 
healthy adult volunteers, were cultured to passage 3 in α-modified MEM, supplemented with 10% 
foetal calf serum (FCS), 0.1 mM Ascorbate-2-Phosphate and additives (2 mM L-glutamine, 100 
μg/mL Streptomycin, 100 U/mL Penicillin, 1 mM Sodium pyruvate, 15 mM HEPES), subsequently 
referred to as growth medium. 
UE7T-13 cells, an immortalised human mesenchymal stem cell line over-expressing human 
telomerase reverse transcriptase (hTERT) and Human papillomavirus transforming protein E7, were 
purchased from the Japanese Collection of Research Bioresources Cell Bank (JCRB Cell Bank, 
Osaka, Japan) and cultured in growth medium. 
All cells were cultured in a humidified incubator with 5% CO2 at 37
oC and expanded (1:3) every 3 
days. 
Cell treatments 
Cells were treated with insulin, IGF-1, arginine, leucine or a combination thereof.  Physiological 
reference values for the concentration of insulin was selected based on Li et. al. 201932; IGF-1 on 
Zhu et. al. 201733 and arginine and leucine on Trabado et. al. 2017.34 
Cell viability 
Cell viability was assessed by measuring DAPI (4’,6- Diamidino-2-Phenylindole, Dihydrochloride) 
uptake by flow cytometry.  Briefly, treated UE7T-13 cells were trypsinised, pelleted at 400 x g and 
resuspended in flow assay buffer (phosphate buffered saline, 1% FCS, 20mM HEPES and 5mM 
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EDTA, pH 7.2).  DAPI was added to a final concentration of 0.2 μM 10 minutes prior to analysis by 
flow cytometry (BD FACSCanto™ II Cell Analyzer, BD Biosciences, USA). 
Western blot analysis 
UE7T-13 cells were seeded onto 60 mm dishes at 3x105 cells in 3 mL of growth medium overnight 
to allow for adhesion.  Cells were then washed with 2 mL of DMEM Ham’s F-12 without Arginine, 
Leucine and Lysine with 0.1 mM Ascorbate-2-Phosphate and additives (referred to as nutrient deplete 
medium) and starved in 3 mL of nutrient deplete medium for between 24 and 72 hours.  Cells were 
pulsed with indicated factor(s) prior to lysis in 100 μl of modified radioimmunoprecipitation assay 
(RIPA) buffer as previously described.29  Total protein (25 μg) from each sample was resolved by 
11% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred at 
100V for 1 hour onto polyvinylidene difluoride (PVDF) membranes.  After blocking with 5% (w/v) 
bovine serum albumin (BSA) in 1X Tris-buffered saline containing 0.1% Tween-20 and 0.05% 
sodium azide (TBS-T) for >1 hour, immunoblotting was performed using the antibodies described 
(Table 1).  Membranes were imaged using LI-COR Odyssey CLx imaging system and Image Studio 
Lite software (version 5.2, LI-COR). 
Table 1:  Antibodies used for immunoblotting. 
Type Manufacturer Catalogue 
Number 
Name Dilution 
Primary Cell Signaling 
Technology 
#2215 Rabbit anti-phospho-ribosomal protein 
S6 at serine 240/244 (pS6 (S240/244), 
1:1000 
Secondary Thermo Fisher #SA5-35571 Goat anti-rabbit IgG (H+L) Secondary 
Antibody, DyLight 800 4X PEG 
1:20000 
Primary Abcam #ab6160 Rat anti-tubulin YL1/2 (α-tubulin) 1:2500 
Secondary Thermo Fisher #SA5-10022 Goat anti-rat IgG (H+L) Cross-Adsorbed 




Differentiation of MSCs 
Primary human MSCs (n=3) were seeded into flat-bottomed 96-well plates at 8x103 cells/well in 
growth media and allowed to adhere overnight.  For induction, media was changed to osteogenic 
media (DMEM low glucose (#D9443) with 5% FCS dialysed as per manufacturer’s instructions 
(Fisher Scientific), 0.4 mM Lysine-HCl, 2.64 mM KH2PO4, 0.1 μM dexamethasone sodium 
phosphate (Mayne Pharma Pty Ltd, South Australia, Australia), 0.1 mM Ascorbate-2-Phosphate and 
additives supplemented with either: 5 ng/mL IGF-1 (-AA); 10 μM arginine, 10 μM leucine and 5 
ng/mL IGF-1 (Low AA); 150 μM arginine, 200 μM leucine and 5 ng/mL IGF-1 (High AA) or 150 
μM arginine, 200 μM leucine, 10 nM rapamycin and 5 ng/mL IGF-1 (High AA + Rapamycin).  Media 
was changed twice weekly for up to 4 weeks.   
Mineral Quantitation 
Mineral quantitation was performed using Calcium Arsenazo III, after solubilising mineral in 0.6 M 
HCl overnight at 4°C and normalised to total DNA content using fluorometric DNA quantitation 
(Invitrogen Quanti-iT Pico Green dsDNA Assay Kit). 
RNA Extraction and Quantitative Reverse-Transcription Polymerase Chain Reaction (qRT-PCR) 
MSCs were seeded into 12 well plates at 6x105 cells/plate and cultured under conditions specified in 
Differentiation of MSCs.  RNA was extracted with 1mL/well TRIzol (Invitrogen) as per 
manufacturer’s instructions (Thermo Fisher).  Isolated RNA was quantitated by Nanodrop 8000 
spectrophotometer (Thermo Fisher).  1 μg of total RNA was reverse transcribed into complementary 
DNA (cDNA) using random hexamers and SuperScript IV Reverse Transcriptase (Invitrogen) as per 
manufacturer’s instructions (Thermo Fisher).  PCR reactions were performed with gene specific 
primers, outlined in Table 2, and SYBR® Green using BioRad CFX 9000qPCR machine (BioRad, 
Hercules, CA, USA).  Gene expression, relative to the housekeeping gene β-actin, was determined 





Statistical analyses were performed using GraphPad Prism 8.0.  Values reported as mean ± standard 
deviation (SD) or standard error of the mean (SEM).  Data were analysed using One-way ANOVA 
with Tukey’s post-hoc test.  P-values less than 0.05 were considered statistically significant. 
Ethical Conduct of Research 
In vitro experiments were conducted in accordance with SAHMRI ethics SAM282 and primary 
human MSCs were obtained from healthy adults following informed consent in accordance with 
procedures approved by the Royal Adelaide Hospital Ethics Committee. 
  




Forward (5’ – 3’) Reverse (5’ – 3’) 
ALPL NM_000478 GTTCCCGGTGCAACACCAC CTCGTTGTCTGAGTACCAGTCCC 
BGLAP NM_199173 ATGAGAGCCCTCACACTCCTCG GTCAGCCAACTCGTCACAGTCC 
ACTB NM_001101 GATCATTGCTCCTCCTGAGC GTCATAGTCCGCCTAGAAGCAT 
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  Results 
Activation of the mTORC1 complex in response to arginine, leucine and IGF-1 in MSCs is poorly 
described.  To investigate this, an immortalised human MSC cell line, UE7T-13, was used as a model 
system.  These cells express all the cell surface markers indicative of an immature MSC including 
STRO-1, STRO-3, STRO-4, CD73, CD90, CD105, CD106 and CD166.36  To measure mTORC1 
activation, phosphorylation of rpS6, a downstream effector of mTORC1, was used.   
UE7T-13 cells remain viable after starvation of arginine, leucine, lysine and FCS for 72 hours. 
To observe differences between basal and stimulated rpS6 phosphorylation, it was important to 
reduce basal levels by starving the cells.  To optimise the starve duration of UE7T-13 cells, cultures 
were starved of arginine, leucine, lysine and FCS for 24, 48 or 72 hours.   A starve duration of 72 
hours showed the greatest reduction in basal rpS6 phosphorylation (Fig. 2A-C), without affecting cell 
survival (Fig. 2D).  Therefore, all subsequent pulse experiments were conducted following a 72-hour 





Figure 2: UE7T-13 cells remain viable after starvation of arginine, leucine, lysine and FCS 
for up to 72 hours.  UE7T-13 cells were treated with 100nM insulin or 100 ng/mL IGF-1 for up 
to 60 minutes after starvation in nutrient deplete medium for (A) 24, (B) 48 and (C) 72 hours.  Cell 
lysates were collected, then analysed by SDS-PAGE and Western blotting using antibodies as 
indicated.  M = protein markers, UT = untreated.  (D) Viability of UE7T-13 cells after 24, 48 or 72 
hr starvation.  Data presented as mean ± SD, One-way ANOVA. 
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IGF-1, arginine and leucine stimulate rpS6 phosphorylation in human MSCs.   
Western blotting was performed to determine whether human MSCs respond to insulin, IGF-1, 
arginine and leucine.  Both insulin and IGF-1 stimulate rpS6 phosphorylation in UE7T-13 cells after 
15 or 60 minutes, irrespective of the starve period (Fig 2A-C), with 60-minute stimulation, following 
72 hours starvation, showing the greatest differential from basal levels (Fig. 2C). 
Physiological levels of arginine and leucine individually do not increase rpS6 phosphorylation 
compared to the untreated control.  However, when administered in combination, they act 
synergistically to increase rpS6 phosphorylation of human MSCs, suggesting that both arginine and 
leucine are required to promote mTORC1 activation (Fig. 3). 
 
Figure 3: Arginine and leucine stimulate rpS6 phosphorylation in human MSCs.  UE7T-13 
cells were starved for 72 hours, then treated with 300 μM arginine, 200 μM leucine or both for 60 
minutes.  Cell lysates were collected, then analysed by SDS-PAGE and Western blotting using 





Sustained rpS6 phosphorylation of UE7T-13 cells by arginine, leucine and IGF-1 is mTORC1-
dependent.   
To characterise the response of UE7T-13 cells to arginine, leucine and IGF-1, a time course was 
performed.  A time-dependent increase in rpS6 phosphorylation was observed between 5 and 60 
minutes in +Arg+Leu treatment, which decreased by 120 minutes.  A similar time-dependent increase 
was observed in the +Arg+Leu+IGF-1 group, however IGF-1 promoted further rpS6 phosphorylation 
compared to the same timepoints in the +Arg+Leu group (Fig. 4A).   Moreover, rpS6 phosphorylation 
was sustained at 120 minutes when treated with AAs and IGF-1 together (Fig. 4A), indicating that 
AAs and IGF-1 work synergistically to promote rpS6 phosphorylation.  In UE7T-13 cells pre-treated 
with rapamycin, rpS6 phosphorylation was reduced to below starvation levels in the presence and 






Figure 4: Sustained rpS6 phosphorylation of UE7T-13 cells by arginine, leucine and IGF-1 is 
mTORC1-dependent.  UE7T-13 cells were starved for 72 hours then treated with 300 μM arginine 
and 200 μM leucine, 100 ng/mL IGF-1 or both treatments together for (A) between 5 and 120 
minutes or (B) 60 minutes with or without 60-minute pre-treatment with 10 nM rapamycin. Cell 
lysates were collected, then analysed by SDS-PAGE and Western blotting using antibodies as 





Arginine and leucine exhibit a titratable effect on rpS6 phosphorylation at 5ng/mL IGF-1.   
To test the hypothesis that arginine and leucine work synergistically with IGF-1 to stimulate 
mTORC1-dependent osteogenesis, it was important to establish culture conditions in which the 
concentrations of arginine and leucine were limiting.  Firstly, a titration of IGF-1 without AAs was 
performed (Fig. 5A).  It was determined that between 3.125 ng/mL and 12.5 ng/mL would be ideal 
as rpS6 phosphorylation appeared to be saturated at 25 ng/mL IGF-1.  10 ng/mL IGF-1 was selected 
to perform titrations of arginine and leucine (Fig. 5B) however, differences between AA 
concentrations was difficult to determine.  Moreover, in the absence of arginine and leucine, 10 
ng/mL IGF-1 alone stimulated robust rpS6 phosphorylation.  Consequently, this concentration was 
halved to 5 ng/mL IGF-1, and a second AA titration was performed.  As shown in Fig. 5C, distinct 
AA concentration-dependent differences in rpS6 phosphorylation were observed enabling the 
nomination of a ‘Low AA’ group (10 μM arginine and 10 μM leucine) and a ‘High AA’ group (150 




Figure 5: Arginine and leucine exhibit a titratable effect at 5ng/mL IGF-1.  (A) UE7T-13 cells 
were treated with increasing concentrations of IGF-1 for 60 minutes.  (B) Increasing AA 
concentrations were applied for 60 minutes in combination with 10 ng/mL IGF-1 and (C) 5 ng/mL 
IGF-1.  Cell lysates were collected, then analysed by SDS PAGE and Western blotting using 





High amino acid levels stimulate early and late stage markers of osteogenesis. 
To determine the effect of arginine and leucine concentrations on osteogenesis, temporal regulation 
of ALPL and BGLAP genes, early and late markers of osteogenesis respectively,37, 38 were measured 
throughout the 28-day induction period.  Consistent with ALPL as an early osteoblastic marker, 
increased levels of expression were observed at Day 7 and Day 14 for all treatment groups when 
compared to Day 0 (Fig. 6A).  Importantly, at Day 14, the High AA group showed a significantly 
higher fold increase in ALPL expression, which was inhibited in the rapamycin treated group, 
implying an mTORC1-dependent mechanism.  Day 7 reflected the same trends without statistical 
significance (Fig. 6A).  At Day 21, the late-stage differentiation marker BGLAP was induced at low 
levels in the -AA and Low AA groups.  Moreover, the High AA group showed the greatest expression, 
which was reduced by administration of rapamycin, suggesting this response is mTORC1-dependent.  
Despite a lack of statistical significance, this mirrors the trends observed in ALPL expression at Days 
7 and 14 (Fig 6B).  Together, these data suggest that AA availability is a driving factor for 








Figure 6: Effect of modulating arginine and leucine on temporal expression of osteo-related 
genes.  Gene expression levels for (A) Alkaline phosphatase (ALPL) and (B) Osteocalcin (BGLAP) 
were determined by qRT-PCR.  Treatment groups: -AA = 5 ng/mL IGF-1; Low AA = 10 μM 
arginine, 10 μM leucine and 5 ng/mL IGF-1; High AA = 150 μM arginine, 200 μM leucine and 5 
ng/mL IGF-1; High AA + Rapamycin = 150 μM arginine, 200 μM leucine, 10 nM rapamycin and 
5 ng/mL IGF-1.  Data are presented as mean ± SEM for n=3 donors, performed in triplicate, 
Statistical significance was determined by One-way ANOVA and Tukey’s post-hoc test (ALPL 
Day 14: -AA vs. High AA, p=.0019; Low AA vs. High AA, p=.026 and High AA vs. High AA + 





Arginine and leucine levels do not significantly affect cell mineralisation. 
To determine whether calcified mineral deposition reflected the observed trends in osteo-related gene 
expression, a calcium assay was performed and normalised to DNA content to consider effects on 
cell proliferation.  Modulating the concentration of AAs however, had no significant effect on cell 
mineralisation at Day 21 or Day 28 post-induction nor does it appear that there were any trends 




Figure 7: Arginine and leucine levels do not significantly affect cell mineralisation.  Calcified 
mineral normalised to DNA content at (A) Day 21 and (B) Day 28 for n= 3 donors/treatment group.  
Treatments: IGF-1 only = 5 ng/mL IGF-1; Low AA = 10 μM arginine, 10 μM leucine and 5 ng/mL 
IGF-1; High AA = 150 μM arginine, 200 μM leucine and 5 ng/mL IGF-1 and High AA + 
Rapamycin = 150 μM arginine, 200 μM leucine, 10 nM rapamycin and 5 ng/mL IGF-1.  No 




Diseases of low bone mass are increasing in prevalence globally in keeping with an ageing 
population.  Low bone mass is likely due to an imbalance in MSC differentiation leading to the 
suppression of osteoblastogenesis in older age.8  Increasing AA intake, through a high protein diet, 
has been shown to not only promote increases in bone mass, but also decrease risk of fracture.13  The 
mTORC1 signalling pathway has been well-established in anabolic processes, but its role in 
osteogenic differentiation of MSCs in response to AAs and IGF-1 is unclear.  Throughout this study, 
the mTORC1-dependent effects of AAs and IGF-1 on human MSCs were investigated in an in vitro 
model.   
Dietary proteins contain essential and conditionally essential AAs including arginine and leucine, 
which have been shown to stimulate production of IGF-1 to promote bone anabolism14, 19.  In this 
study, we were able to successfully determine that human MSCs are responsive to arginine, leucine 
and IGF-1 in an mTORC-1 dependent manner, implicating the pathway in the human response to 
dietary protein.  It is interesting to note that the synergistic effect that arginine and leucine had on 
rpS6 phosphorylation has not been described previously31, which may indicate that GATOR2 requires 
inputs in addition to arginine or leucine individually.  In keeping with this idea, we also found that, 
in UE7T-13 cells, rpS6 phosphorylation can be stimulated through the addition of lysine as well as 
arginine and leucine during pulse experiments (Fig. S1).   
Recent studies have found that increased mTORC1 signalling increases osteogenic markers including 
Alpl39 and Ocn40 in vitro as well as increasing bone mass in ovariectomised mice.39, 40  We were able 
to show that induction of ALPL and BGLAP, at early and late stages of osteogenesis respectively, was 
inhibited through the inclusion of rapamycin, demonstrating that AAs promote osteogenesis via 
mTORC1.  Statistical significance could not be achieved for ALPL at Day 7 or BGLAP at Day 21 due 
to high donor variability.  Therefore, differentiation assays with additional donors may be required to 
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produce more conclusive evidence.  Together, these data suggest that AAs may influence the 
differentiation program in human MSCs through mTORC1. 
Observing an increase in expression of ALPL at Days 7 and 14 and BGLAP at Day 21 in the High AA 
group compared to other groups led us to hypothesise that cell mineralisation would follow the same 
trend however, this was not the case.  Despite our study finding no significant effect or obvious trend 
between groups at Days 21 and 28, we acknowledge that dexamethasone, one of the key drivers of 
osteogenic differentiation of MSCs in vitro41, has been shown to activate REDD142 in skeletal muscle, 
which is an inhibitor of mTORC1 though the TSC.43  Whether REDD1 inhibits mTORC1 in a similar 
manner in the bone microenvironment though has not been investigated.  As a result, optimisation 
studies are required to modify osteogenic media to exclude dexamethasone and therefore determine 
the true effect of modulating AAs on cell mineralisation.   
Alkaline phosphatase has been shown to be a critical regulator of bone mineralisation in mice.44  
Throughout the 28-day induction period, neither ALPL nor BGLAP expression was upregulated in the 
-AA group suggesting that calcified mineral could not form due to lack of osteoblast differentiation.  
It is currently unknown whether human MSCs can survive in arginine and leucine free conditions for 
extended periods, so it is plausible that the observed signal was representative of artefacts from a 
compensatory mechanism or cell death through apoptotic or necrotic pathways. 
A relationship between AAs and IGF-1 production45 as well as the role of IGF-1 in promoting 
osteoblastic differentiation of MSCs through activation of mTOR20 has been established however, 
whether these events are related has not been described.  Data from this study suggest that AAs 
promote mTORC1 activation inferring that these may be correlated.  It is possible that MSCs could 
be responding to AAs by stimulating mTORC1-dependent IGF-1 synthesis and secretion to act in an 
autocrine or paracrine manner to induce osteoblast differentiation.  Therefore, the effect of AAs on 
IGF-1 gene expression as well as IGF-1 protein levels warrants enquiry. 
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Currently, in Australia, National Health and Medical Research Council guidelines recommend higher 
protein intake for older individuals.46  A high protein diet has previously been proposed as having 
detrimental effects on bone health, known as the acid-ash hypothesis.1  This was speculated due to 
increased urinary calcium excretion observed in individuals with high dietary protein intake.47  It was 
thought that this caused increased renal acid load, subsequently resulting in calcium, as well as other 
alkaline minerals, to be released from the bone to neutralise it.48  It has since been shown that an 
increase in dietary protein causes increased calcium absorption, allowing for acid neutralisation to 
occur with serum calcium rather than calcium derived from bone.49  Further elucidation of the 
mechanism behind how high dietary protein intake influences bone mass could help to inform dietary 
guidelines, particularly for the elderly and those at risk of diseases characterised by low bone mass.  
Additionally, it would allow exploration of the possibility of developing anabolic agents for low bone 
mass treatments. 
This is the first study to date to assess the response of MSCs to both the AA sensing and growth factor 
branches of the mTORC1 pathway in a human context.  Other research has primarily investigated 
each facet of the pathway individually or focussed on substrates that induce anabolic processes 
through mTORC1.  Now that evidence of a mTORC1-dependent relationship between AAs, IGF-1 
and human MSCs has been established, further investigation to elucidate the mechanism behind the 
response of dietary protein intake and MSC differentiation, and therefore bone formation, can be 
conducted.   
In summary, results from this study suggest that arginine, leucine and IGF-1 promote mTORC1 
signalling in human MSCs and modulating AA concentration influences gene expression of early and 
late osteogenic markers, ALPL and BGLAP.  While we could not deduce with certainty whether 
modulating AA concentration influences MSC mineralisation, optimisation of the protocols used will 
provide some clarity.  Studies in the near future will optimise differentiation protocols, assess IGF-1 
production by MSCs and investigate the mTORC1-dependent effects of AAs and IGF-1 on MSC and 
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osteoblast biology in vivo, while longer-term studies will assess the osteoclastic division of bone 
remodelling. 
Word count: 4499  
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Figure S1. Lysine promotes further synergism of the mTORC1 response to AAs in the 
absence of IGF-1.  UE7T-13 cells were starved for 72 hours, then treated with 300 μM arginine, 
200 μM leucine, 300 μM lysine or 100 ng/mL IGF-1 60 minutes, with or without 60-minute pre-
treatment with 10 nM rapamycin.  Cell lysates were collected, then resolved by 9% SDS-PAGE 
and Western blotting using antibodies as indicated.  M = protein markers, Replete = nutrient deplete 
media supplemented with 10% FCS, 300 μM arginine, 200 μM leucine, 300 uM lysine and 100 
ng/mL IGF-1. 
 
